Avastin Shows No Benefit Against Early Stage Co... ( 'Disappointing' results may yet be re...)

Avastin Shows No Benefit Against Early Stage Colon Cancer

Date:5/30/2009

'Disappointing' results may yet be reversed with longer-term study, researchers say

SATURDAY, May 30 (HealthDay News) -- The cancer drug Avastin, widely used for lung, breast and metastatic colorectal cancers, appears ineffective for patients with early stage colon cancer, a result the trial's lead author called "disappointing."

"There's no sense of building up a false sense of anticipation and drama. We failed to provide patients with a novel intervention which would increase the cure rate," said that author, Dr. Norman Wolmark, chairman of the department of human oncology at Allegheny General Hospital in Pittsburgh and chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), which conducted the study.

But at a news conference, held Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla., Wolmark pressed the point that Avastin (bevacizumab) did bring an improvement while it was given to patients. However, this benefit vanished once patients stopped taking the drug.

"The hoped-for endpoints of the trial -- to increase the cure rate of early stage colon cancer -- were simply not met," he said. "Having said that, it is clear that there was a statistically significant transient benefit in disease-free survival during the time that [Avastin] was given, so it was effective. But, that efficacy disappeared after the year that it was given."

At one year, there was an absolute difference in disease-free survival of only 3.6 percent in favor of Avastin. And the jury may still be out on whether or not Avastin's benefits might last if patients receive it for a longer period of time. "Clearly, strong consideration should be given to clinical trials that use [Avastin] for periods of time beyond the one year that was used in this protocol," Wolmark said.

The trial, a large one involving 2,710 patients from 245 institutions, was funded by the U.S.
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration
2. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
3. Avastin effective at delaying brain tumor progression in recurrent disease
4. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
5. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
6. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
7. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
8. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
9. Avastin Added to Chemo Helps Women With Advanced Cancer
10. Off-Label Avastin Use for Wet Macular Degeneration
11. FDA OKs Avastin for Advanced Breast Cancer

Post Your Comments:

Avastin Shows No Benefit Against Early Stage Co...( 'Disappointing' results may yet be re...),Health